SEC ownership of MEDIFAST INC

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000910329.

Comparable stake leader

RENAISSANCE TECHNOLOGIES LLC

Disclosed value leader

BlackRock, Inc.

Comparable rows

50/50

Latest evidence

26 May 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
RENAISSANCE TECHNOLOGIES LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
26 May 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0000910329
Issuer location
Baltimore, MD

Ownership snapshot

Top shareholders of MEDIFAST INC (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RENAISSANCE TECHNOLOGIES LLC
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
26 May 2026
13D/G 13F 3/4/5 Lead comparable stake: 7% 13D/G row: RENAISSANCE TECHNOLOGIES LLC Showing 1-8 of 50 holder rows.

Quick read

RENAISSANCE TECHNOLOGIES LLC leads the comparable SEC ownership view at 7%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RENAISSANCE TECHNOLOGIES LLC's linked filing trail.
Comparable ownership Top 5
RENAISSANCE TECHNOLOGIES LLC 7%
Citadel Securities GP LLC 6.5%
Steamboat Capital Partners, LLC 6%
CHARLES SCHWAB INVESTMENT MANAGEM... 5.7%
BlackRock, Inc. 2.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RENAISSANCE TECHNOLOGIES LLC
13D/G 13F
Company
7%
$8,139,429
773,710 shares
-$1,212,093 02 Jan 2026
Citadel Securities GP LLC
13D/G
6.5%
$7,531,373
715,910 shares
$0 31 Mar 2026
Steamboat Capital Partners, LLC
13F 13D/G
Company
6%
from 13D/G
$7,210,342
707,590 shares
31 Mar 2026
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
13F 13D/G
Company
5.7%
from 13D/G
$6,435,382
631,539 shares
31 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
2.9%
from 13D/G
$9,623,975
944,453 shares
31 Mar 2026
SUSQUEHANNA SECURITIES, LLC
13D/G
G1 Execution Services, LLC
1.4%
$1,741,155
148,944 shares
-$5,915,152 31 Dec 2025
Parsa Kiai
3/4/5
Director
6.1%
$7,100,357
693,910 shares
26 May 2026
Daniel R. Chard
3/4/5
Chairman & CEO, Director
3.1%
$3,787,830
355,609 shares
+$178,725 13 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$241,675.

Buys
$241,675
Insiders: 2
Sells
$0
Insiders: 0
Net
+$241,675
Shares: +22,678
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 22,678 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 5,000 0 $62,950 $0 +$62,950
3-6 17,678 0 $178,725 $0 +$178,725
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-14 of 14 reporting-owner rows connected to MEDIFAST INC. Open a relationship link for the CIK-to-CIK filing trail.

Rows
14
Largest Forms 3/4/5 holder
Parsa Kiai
Net 12M change
+$241,675
Latest report
26 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Parsa Kiai Director $7,100,357 Mixed 26 May 2026
Daniel R. Chard Chairman & CEO, Director $3,787,830 +$178,725 +5% Mixed 13 Mar 2026
Kevin G. Byrnes Director $1,027,977 Mixed 11 Nov 2021
James P. Maloney Chief Financial Officer $779,992 Mixed 13 Mar 2026
Jeffrey J. Brown Director $573,487 Mixed 25 Jun 2025
Ming Xian Director $430,393 Mixed 26 May 2026
Scott Schlackman Director $430,310 +$62,950 +17% Mixed 26 May 2026
Andrea B. Thomas Director $363,753 Mixed 26 May 2026
Michael A. Hoer Director $351,575 Mixed 25 Jun 2025
Elizabeth A. Geary Director $318,182 Mixed 26 May 2026
Jonathan Barrett MacKenzie VP, Finance & CAO $222,549 Mixed 13 Mar 2026
Nicholas Mark Johnson President $195,833 Mixed 05 Jan 2026
Jeffrey Matthew Rose Director $187,689 Mixed 26 May 2026
Constance J. Hallquist Former Director $148,251 Mixed 06 Oct 2023

Recent insider transactions for MEDIFAST INC

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Jeffrey Matthew Rose MED Common Stock Award 18,419 18,419 26 May 2026 Direct
Parsa Kiai MED Common Stock Award 19,317 19,317 26 May 2026 Direct
Andrea B. Thomas MED Common Stock Award 48.6% 11,680 35,697 26 May 2026 Direct
Scott Schlackman MED Common Stock Award 38.2% 11,680 42,229 26 May 2026 Direct
Elizabeth A. Geary MED Common Stock Award 59.8% 11,680 31,225 26 May 2026 Direct
Ming Xian MED Restricted Stock Units (cash settled) Award 36.3% 11,680 43,823 26 May 2026 Direct
Scott Schlackman MED Common Stock Purchase 8.91% $31,325 $12.53 2,500 30,549 11 May 2026 Direct
Scott Schlackman MED Common Stock Purchase 9.79% $31,625 $12.65 2,500 28,049 08 May 2026 Direct
Jonathan Barrett MacKenzie MED Common Stock Award 108.2% 10,830 20,838 25 Mar 2026 Direct
Jonathan Barrett MacKenzie MED Common Stock Tax liability -7.93% -862 10,008 25 Mar 2026 Direct
James P. Maloney MED Common Stock Award 93.8% 35,358 73,033 25 Mar 2026 Direct
James P. Maloney MED Common Stock Tax liability -7.88% -3,224 37,675 25 Mar 2026 Direct
Daniel R. Chard MED Common Stock Award 28.5% 41,795 188,233 25 Mar 2026 Direct
Daniel R. Chard MED Common Stock Tax liability -12.1% -20,095 146,438 25 Mar 2026 Direct
Daniel R. Chard MED Common Stock Purchase $178,725 $10.11 17,678 17,678 20 Mar 2026 Dan and Allyson as Joint Tenants
Jonathan Barrett MacKenzie MED Common Stock Tax liability -0.64% -70 10,870 17 Mar 2026 Direct
James P. Maloney MED Common Stock Tax liability -1.16% -482 40,899 17 Mar 2026 Direct
Daniel R. Chard MED Common Stock Tax liability -1.56% -2,638 166,533 17 Mar 2026 Direct
Jonathan Barrett MacKenzie MED Common Stock Tax liability -1.78% -198 10,940 13 Mar 2026 Direct
James P. Maloney MED Common Stock Tax liability -2.17% -918 41,381 13 Mar 2026 Direct
Daniel R. Chard MED Common Stock Tax liability -4.01% -7,075 169,171 13 Mar 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .